Intrinsic Imaging Awarded Phase I/II Trial of Novel Cancer Therapy
News Jul 15, 2013
During this trial, Intrinsic Imaging will process all images and evaluate treatment response of the patient’s metastatic cancer.
Intrinsic Imaging, an FDA audited, ISO 9001 and ISO 13485 certified imaging core lab specializing in providing imaging core lab services for clinical trials, announced that it was awarded a multicenter Phase I/II clinical trial designed to evaluate a new therapy to treat patients with metastatic colorectal cancer (mCRC).
This clinical research study utilizes a novel investigational biologic treatment for patients with unresectable liver metastases in patients with colorectal cancer. During this trial, Intrinsic Imaging will process all images and evaluate treatment response of the patient’s metastatic cancer.
“Advances in medical research have created several new options focused on the treatment of metastatic colorectal cancer. There remains, however, significant challenges in achieving long-term survival in those patients with metastatic disease. The continued development and evaluation of novel therapies is necessary to benefit patients suffering from this disease,“ said Dr. Amit Mehta, Chief Medical Officer, Intrinsic Imaging.
Intrinsic Imaging’s team of more than sixty board-certified diagnostic radiologists has sub-specialization in all therapeutic areas including, but not limited to, Oncology, Cardiovascular and Thoracic, Central Nervous System, Gastrointestinal & Genitourinary, Musculoskeletal, and Medical Device. The Intrinsic Oncology team consists of 12 fellowship trained board-certified radiologists, and 8 board-certified interventional radiologists who have in-depth experience in, colorectal, pancreatic, breast, lung, ovarian and prostate cancer, among others.
“Colorectal cancer (CRC) continues to be a global public health problem with over 1 million new cases diagnosed each year. Intrinsic Imaging is dedicated to applying our therapeutic and regulatory expertise throughout this clinical trial towards assisting in the development of a new effective therapy to treat patients with metastatic colorectal cancer,” said Todd A. Joron, BSc. MBA, President and Chief Operating Officer, Intrinsic Imaging.
Arsenic Trioxide Could Extend Lives of Patients with Aggressive Brain CancerNews
Arsenic trioxide could be a powerful therapy that could extend the lives of certain glioblastoma patients by as much as three to four times the median expectation.READ MORE
XenoGesis and Juniper Pharma Services Strengthen AllianceNews
Campanies extend strategic alliance in early drug development services.READ MORE
Quotient Clinical Signs Cocrystal Agreement with NuformixNews
Partnership to evaluate cocrystal formulations using translational pharmaceutics.READ MORE
Comments | 0 ADD COMMENT
Annual Conference on Antimicrobials and Drug Resistance
Sep 24 - Sep 25, 2018
1st Alpine Winter Conference on Medicinal and Synthetic Chemistry
Jan 28 - Feb 01, 2018